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Abstract
The role of brain-derived neurotrophic factor (BDNF) and its receptor TrkB has been studied in the context of mood disorders and
their treatments for a couple of decades. Pharmacologically diverse antidepressant drugs increase the synthesis of BDNF in the
cortex (and some subcortical structures) and this effect accounts for their ability to facilitate neurotrophic processes eventually
leading into heightened plasticity within the cortex. Induction of BDNF-TrkB signaling has also been associated with the
mechanism of action of ketamine and more recently with some other anesthetics, even with ones not thought to possess
antidepressant potential. Notably, both ketamine and conventional antidepressants activate TrkB receptor and its downstream
signaling rapidly within the same time scale in the brain while electroconvulsive therapy (ECT), among the most potent inducers
of BDNF, has not been unequivocally shown to produce such acute effects on TrkB. The ability of antidepressants to regulate
TrkB signaling is developmentally regulated and requires an intact central nervous system. The purpose of this review is to
highlight and discuss some of these peculiarities associated with the effects of ketamine and classical antidepressants and BDNF
on TrkB signaling.
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Introduction
The therapeutic effects of chemically induced seizures against
neuropsychiatric disorders, most notably schizophrenia and
severe depression, provided a rational basis for the develop-
ment of electroconvulsive therapy (ECT) (Payne and Prudic
2009). Since its initial clinical implementation in 1938, the
antidepressant effects of ECT have been well documented.
The first antidepressant drugs, a chlorpromazine derivative
imipramine and an isoniazid derivative iproniazid, were dis-
covered in the 1950s. Their pharmacological mode of action
was soon traced down to facilitation of monoaminergic tone,
which rationalized the subsequent development of pharmaco-
logically similar compounds. Of these drugs, the serotonin/
norepinephrine selective reuptake inhibitors are the first-line
medications in the treatment of depression today. However,
overall remission rates to these medications are low and there
is a delayed onset before the effects on the core symptoms of
depression become evident (Fava 2003). The relatively recent
discovery of the rapid antidepressant effects of ketamine, an
N-methyl-D-aspartate (NMDA) receptor antagonist (Berman
et al. 2000; Aan Het Rot et al. 2012), has generated huge
enthusiasm to develop novel antidepressants with better effi-
cacy and a faster onset of therapeutic action. While there is
little doubt on the antidepressant effects of ketamine, the pre-
cise neurobiological basis of its therapeutic actions—as with
classical antidepressants and ECT—remains to be unknown.
Emerging experimental data however suggest that induction
of intrinsic regenerative and neurotrophic mechanisms and
subsequent facilitation of synaptic plasticity significantly con-
tribute to antidepressant effects (Castrén and Rantamäki 2010;
Duman and Aghajanian 2012; Castrén and Hen 2013). It is
increasingly recognized that upregulation of brain-derived
neurotrophic factor (BDNF) synthesis and release and activa-
tion of its neurotrophin receptor tropomyosin-related kinase B
(TrkB) are at the core of these alterations, as reviewed else-
where (Duman and Monteggia 2006; Rantamäki and Castrén
2008; Castrén and Rantamäki 2010; Duman and Aghajanian
2012; Castrén and Hen 2013). Less attention has been put on
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some of the discrepancies and obscurities related to the effects
of antidepressants on TrkB. Before highlighting and
discussing these, it is important to introduce some of the basic
principles of BDNF-TrkB signaling machinery.
An overview of BDNF-TrkB signaling
BDNF belongs to the neurotrophin family of neurotrophic
factors (Barde et al. 1982). Neurotrophins are ~ 14-kDa gly-
coproteins that support the survival and differentiation of spe-
cific neuronal populations in the peripheral nervous system
during development (Huang and Reichardt 2001). In the de-
veloping brain, BDNF regulates the differentiation, matura-
tion and function of many neuronal subtypes, especially the
GABAergic (γ-aminobutyric acid) interneurons (Huang et al.
1999). BDNF is the most widely expressed neurotrophin in
the adult brain wherein the most prominent expression is ob-
served at the level of the hippocampus and cerebral cortex.
BDNF is, however, also found, e.g., in the blood that is
thought to arise mainly from circulating platelets (Rosenfeld
et al. 1995; Chacón-Fernández et al. 2016). The levels of
BDNF in the human serum are in fact very high (~ 5–25 ng/ml;
see below). The levels of BDNF in the mouse serum are in-
stead low or undetectable (Chacón-Fernández et al. 2016).
Among neurotrophins, the role of BDNF in regulating syn-
aptogenesis and synaptic plasticity (e.g., long-term potentia-
tion (LTP)) in the developing and adult central nervous system
has been best characterized (Thoenen 1995; Hensch 2005;
Park and Poo 2013). These effects of BDNF have been asso-
ciated with the ability of neuronal activity to regulate the ex-
pression, process and release of BDNF.While robust neuronal
excitation, such as generalized seizures (Isackson et al. 1991),
produces prominent increase in BDNF synthesis, physiologi-
cal stimuli such as light (at the level of visual cortex) (Castrén
et al. 1992) and physical exercise (Neeper et al. 1995) also
increase bdnf mRNA levels in the adult hippocampus and
cortex. Like the other so-called immediate-early genes (e.g.,
c-fos, arc, zif-268), the bdnf gene is rapidly but transiently
activated in response to various stimuli.
The bdnf gene structure is complex and due to alternative
splicing, numerous mRNA transcripts can be made (Aid et al.
2007; Pruunsild et al. 2007). These transcripts are, however,
translated and processed into identical pro-BDNF protein that
is further enzymatically processed into mature protein within
or outside the cell (note: the protein sequence of the mature
BDNF is essentially identical among humans and mice). LTP-
inducing paradigms have been shown to increase bdnfmRNA
(Castrén et al. 1993) and concomitant release of pro-BDNF
and tissue plasminogen activator (tPA) from neurons resulting
in plasmin-mediated cleavage of pro-BDNF within activated
synapses in vitro (Pang et al. 2004). Without such conversion,
the levels of pro-BDNF may increase extracellularly allowing
it to bind to the p75NTR, a member of the TNF family of
receptors, whose activation has been associated with opposing
effects on neuronal structure and synaptic plasticity as seen
with BDNF (Teng et al. 2005; Woo et al. 2005). To which
extend this pro-BDNF p75NTR signaling axis influences brain
function under physiological context in vivo is unclear, espe-
cially in the adult brain where the levels of pro-BDNF are low
(Matsumoto et al. 2008) and p75NTR expression is largely
confined in the cholinergic neurons of the basal forebrain.
The neurotrophic and neuroplastic effects of BDNF are
mainly mediated by the TrkB receptor (Klein et al. 1991;
Barbacid 1994; Huang and Reichardt 2001). Full-length
TrkB receptors are ~ 145-kDa membrane bound glycoproteins
(core protein ~ 93 kDa) that bind with high affinity to BDNF
and a lesser extent to NT-3 (neurotrophin-3) and NT-4. TrkB
receptors exist also as truncated forms that lack the majority of
the intracellular domain while the extracellular domain is
identical with the full-length receptors (Middlemas et al.
1991). These receptors act as BDNF scavengers or
dominant-negative regulators of the full-length TrkB (Eide
et al. 1996; Saarelainen et al. 2000), although the biological
role of these receptors appears more complex (Fenner 2012).
Upon binding to BDNF, TrkB receptors dimerize and
transphosphorylate each other within the autophosphorylation
loop (Y705/6) (Fig. 1). These posttranslational modifications
further launch phosphorylation of other tyrosine residues that
serve as docking sites for adaptor proteins that set off complex
intracellular signaling cascades (Huang and Reichardt 2001).
Phosphorylation of the Shc binding site (Y515) ultimately
regulates protein kinase B (AKT) and mitogen-activated pro-
tein kinase (MAPK) pathways that are important regulators of
cell survival and neuronal differentiation. AKT regulates a
number of apoptotic and survival mechanisms and is also an
important regulator of mTor (mammalian target of rapamycin)
and GSK3β (glycogen synthase 3β) (Kim et al. 2001; Beurel
et al. 2015; Hermida et al. 2017). GSK3β is a promiscuous
serine-threonine kinase that regulates a wide variety of cellular
functions including metabolism and differentiation (Beurel
et al. 2015; Hermida et al. 2017). Phosphorylated Y816 serves
as a docking site for the phospholipase-Cγ1 (PLCγ1) that
upregulates [Ca2+]i levels and thereby activation of, e.g.,
calcium/calmodulin kinase pathway. This pathway and
MAPK ultimately regulate gene expression via transcription
factor CREB (cAMP response element binding protein)
(Finkbeiner et al. 1997). Activation of the PLCγ1 pathway
has been shown to be particularly important for TrkB-
induced synaptic plasticity (Minichiello et al. 1999, 2002).
Direct application of BDNF (> 1–5 ng/ml) into cultured neu-
rons readily phosphorylates Y705/6, Y515 and Y816 residues
in TrkB (note: since Trk receptors share close similarity within
their tyrosine kinase domains and the PLCγ1 binding sites, it
is difficult to develop antibodies that specifically detect TrkB
phosphorylation on these sites).
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Despite the indisputable effects of BDNF on neuronal func-
tion and behavior in the brains of adult animals (incl. intracere-
bral applications of BDNF; see, e.g., Siuciak et al. 1994, 1996,
1997; Mamounas et al. 1995) BDNF-TrkB signaling seems to
undergo significant developmental-dependent changes (Fig. 2).
First, in contrast to adult animals, seizures produce negligible
effects on hippocampal bdnf mRNA when delivered during
early postnatal development (< P14) (Dugich-Djordjevic et al.
1992). Moreover, while BDNF strongly phosphorylates TrkB
receptors in cultured neurons and in ex vivo preparations of an
early postnatal brain, the responsiveness of TrkB to BDNF
drastically reduces in a more mature brain. At around the third
postnatal week and thereafter, an application of BDNF produces
only minor effects on TrkB phosphorylation (Knüsel et al.
1994; Di Lieto et al. 2012). This intriguing phenomenon is
unrelated to the gradual increase of dominant-negative truncat-
ed TrkB receptors during postnatal development (Di Lieto et al.
2012). Indeed, an essentially similar developmentally regulated
reduced responsiveness of TrkA (no truncated receptors) to
nerve growth factor (NGF) is observed (Knüsel et al. 1994).
Moreover, basal TrkB phosphorylation levels are strongly re-
duced in the hippocampus of Bdnf-deficient mice during early
development, while no baseline difference is seen in adult mice
(Di Lieto et al. 2012). The neurobiological basis of these
developmental-dependent changes in BDNF-TrkB signaling re-
mains poorly known. For example, p75NTR and SorCS2 recep-
tors, family members of vacuolar protein sorting 10 (VPS10)
domain-containing receptor proteins, have been shown to facil-
itate the responsiveness of TrkB to BDNF (Berg et al. 1991;
Glerup et al. 2016). In the absence of SorCS2, the ability of
BDNF to induce TrkB signaling, LTP and neurotrophic effects
is essentially abolished (Glerup et al. 2016).
The complexity of Trk(B) signaling is further highlighted
by transactivation mechanism. At least glucocorticoids, zinc,
Fig. 1 Effects of BDNF and antidepressants on TrkB receptor signaling.
Upon BDNF binding, TrkB receptors dimerize at the cell surface leading to
transphosphorylation of the autophosphorylation loops (Y705/6) and
phosphorylation of tyrosine residues 515 and 816 that set fourth MAPK/
Akt and PLCγ1 signaling cascades, respectively. Monoaminergic antide-
pressants and isoflurane anesthesia increase phosphorylation of Y705/6
and Y816 within TrkB while leaving Y515 unaffected. Unlike BDNF,
these drugs appear to (trans)activate TrkB receptors (immaturely
glycosylated) residing also in intracellular compartments. BDNF, brain-
derived neurotrophic factor; MW, molecular weight; MAPK, mitogen-
activated protein kinase; CREB, cAMP response element binding protein;
Akt, protein kinase B; mTor, mammalian target of rapamycin; PLCγ1,
phospholipase Cγ1; GSK3β, glycogen synthase kinase 3β; DAG, diacyl-
glycerol; PKC, protein kinase C; IP3, inositol triphosphate; PIP2, phos-
phatidylinositol 4,5-bisphosphate; TCA, tricyclic antidepressant; SSRI,
serotonin-selective reuptake inhibitor
Fig. 2 Contrasting developmental-dependent effects of BDNF and
antidepressants on TrkB. The ability of BDNF to activate TrkB
gradually reduces during early postnatal development in rodents. At
around 2 weeks of age, BDNF brings negligible effects on TrkB while
systemic administrations of antidepressants begin to bring their effects on
TrkB signaling. ADs, antidepressants; BDNF, brain-derived neurotrophic
factor; P, postnatal day; p-TrkB, TrkB phosphorylation
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H2O2, adenosine and pituitary adenylate cyclase–activating
polypeptide (PACAP) can phosphorylate and activate Trk re-
ceptors independently of neurotrophins (Lee and Chao 2001;
Lee et al. 2002; Huang et al. 2008; Jeanneteau et al. 2008;
Huang and McNamara 2010, 2012). Notably, such
transactivation seems to appear also in intracellular compart-
ments, as evidenced by the phosphorylation of low molecular
weight Trk receptors presumably corresponding to immature-
ly glycosylated forms of the receptor (Rajagopal et al. 2004).
While most transactivation mechanisms have been studied in
cultured cells, zinc is shown to activate TrkB also when ad-
ministered systemically in adult mice (Huang et al. 2008). The
effect of zinc and H2O2 on TrkB signaling also becomes evi-
dent rapidly while it takes a few hours for the other
transactivators to bring similar effects in vitro. Src family ki-
nases have been implicated in Trk transaction (Lee and Chao
2001; Huang and McNamara 2010) while other mechanisms
may also be involved.
Pharmacologically diverse antidepressant
drugs target TrkB receptors, but how?
Since the important scientific discoveries demonstrating the
effects of stress and antidepressants on bdnf mRNA levels in
the early 1990s (Smith et al. 1995; Nibuya et al. 1995), the role
of BDNF has been thoroughly studied in the context of mood
disorders and their treatments (Duman and Monteggia 2006;
Castrén and Hen 2013). The opposing effects of stress
(reduction) and classical antidepressant drugs (increase) on
bdnf synthesis in the hippocampus and cortex have been re-
peatedly reported. Notably however, induction of bdnf synthe-
sis is by no means restricted to pharmacological agents carry-
ing antidepressant effects. The effects of classical antidepres-
sant on bdnf mRNA levels emerge gradually within the time
course of a few weeks, which corresponds with the delayed
onset of therapeutic actions of these medications (Nibuya et al.
1995). Changes in bdnf mRNA have been, however, also re-
ported already after a single treatment of monoaminergic an-
tidepressants by some groups (e.g., Zetterström et al. 1999).
Changes in BDNF protein have been reported less consistent-
ly, indicating that the total tissue levels of BDNF are relatively
stable and BDNF is synthesized and released on demand in
active synapses. Only minute amounts of BDNF are released
upon activation, making the investigation of the neuronal re-
lease of BDNF challenging (Balkowiec and Katz 2002), es-
pecially in in vivo settings.
In an (initial; see below) attempt to indirectly investigate the
effects of antidepressants on BDNF release, Dr. Castrén and
colleagues—including myself—assayed TrkB phosphoryla-
tion levels in the brain lysates of mice subjected to antidepres-
sant treatments (Fig. 1). Both imipramine (tricyclic) and fluox-
etine (serotonin-selective reuptake inhibitor) induce TrkB
phosphorylation and phosphorylation of CREB in the adult
rodent cortex within an hour after a single systemic injection
(Saarelainen et al. 2003). These findings were later confirmed
and extended using a battery of pharmacologically distinct
antidepressant drugs (Rantamäki et al. 2007) and with lithium
(Rantamäki et al. 2006). Classical antidepressants activate
TrkB in various brain areas, including the hippocampus, stria-
tum, visual cortex and cerebellum (Saarelainen et al. 2003;
Rantamäki et al. 2007, 2011) (Rantamäki, unpublished).
Notably, antidepressants preferentially increase the phosphor-
ylation of the autophosphorylation loop (Y705/6) and the
PLCγ1 site while leaving the phosphorylation of the Shc bind-
ing site mostly unaffected (Saarelainen et al. 2003; Rantamäki
et al. 2007, 2011; Di Lieto et al. 2012), although amitriptyline
has been shown to phosphorylate all sites (Aonurm-Helm et al.
2015). Indeed, phosphorylation of AKT and MAPK remains
unchanged (or even reduced) after acute antidepressant treat-
ments (Rantamäki et al. 2007; Di Lieto et al. 2012).
Phospho-TrkB antibodies recognize ~ 100–110-kDa band
in brain lysates obtained from antidepressant-treated mice
(Saarelainen et al. 2003; Rantamäki et al. 2011). This protein
may represent the immaturely glycosylated form of the recep-
tor that is often observedwhen Trk receptors are transactivated
independently by BDNF (see above) (Fig. 1). To support this
idea, we have shown that imipramine activates TrkB receptors
also in the hippocampus of forebrain-specific conditional
BDNF knockout mice (Rantamäki et al. 2011). Moreover,
the ability of antidepressants to activate TrkB is developmen-
tally regulated (Di Lieto et al. 2012). A significant effect is
seen in around a 2-week-old mouse and thereafter. This de-
velopmental time window corresponds with the differential
responsiveness of TrkB to BDNF (discussed above) (Fig. 2).
In fact, antidepressants have no effect on TrkB phosphoryla-
tion in culture neurons derived from embryonic rat brain or in
cell lines (Rantamäki et al. 2011), although amitriptyline may
again be an exception (Jang et al. 2009). All in all, the precise
mechanism how antidepressants (trans)activate TrkB remains
to be discovered but an intact and mature central nervous
system seems to be required.
Differential effects of electroconvulsive shock
and anesthesia on TrkB
The therapeutic effects of ECT become evident faster than
those of conventional antidepressants (Segman et al. 1995),
yet reduction of symptoms after a single ECT treatment is only
seldom reported (Rich 1984; Thomas and Kellner 2003;
Fligelman et al. 2016). An electric current leading into a short
epileptiform electroencephalogram (EEG) activity is deliv-
ered during ECT under light anesthesia but how this Bseizure^
leads into a remedy remains a mystery.
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Electroconvulsive shock (ECS; an animal model of
ECT)—and seizures in general—increases bdnfmRNA levels
(and other immediate early genes) in the adult rodent cortex
and hippocampus. The effects appear faster and are in magni-
tude greater than those observed after classical antidepressants
(Nibuya et al. 1995). Indeed, ECS, especially when delivered
repeatedly during a course of several days or weeks, increases
BDNF protein levels (Altar et al. 2003; Hansen et al. 2007;
Segawa et al. 2013; Neyazi et al. 2018). To nail down the
putative involvement of TrkB signaling, we investigated the
effects of ECS on TrkB phosphorylation. Unexpectedly how-
ever, TrkB phosphorylation levels were reduced after a single
ECS treatment (Hansen et al. 2007). Lack of effects on TrkB
was also seen with repeated ECS treatment paradigm, even if
BDNF protein levels were concomitantly increased in the
same samples (Hansen et al. 2007). Since these early attempts,
there has been little interest to investigate the effects of ECS
on TrkB activation, although one recent study showed in-
creased TrkB phosphorylation following repeated administra-
tion of ECS (Enomoto et al. 2017). Notably, brain samples
were collected for analyses 4 h after the last ECS in this study.
Pharmacologically induced seizures on the other hand have
been more consistently shown to lead into increased TrkB
phosphorylation in the adult hippocampus and cortex (Aloyz
et al. 1999; Binder et al. 1999; He et al. 2002, 2004). Here too,
the involvement of BDNF is however unclear as seizure-
induced phosphorylation of TrkB in the hippocampus is read-
ily also seen in conditional Bdnf−/− (synapsin-cre) mice (He
et al. 2004).
A postictal emergence electroencephalogram (EEG) burst
suppression pattern has been associated with the efficacy and
onset-of-action of ECT (Sackeim et al. 1993; Nobler et al.
1993; Tadler and Mickey 2018). This encouraged clinical in-
vestigations to test whether deep burst-suppressing isoflurane
anesthesia can ameliorate depressive symptoms with partially
promising outcomes (Langer et al. 1985, 1995). This
prompted us recently to investigate the effects of isoflurane
on TrkB signaling in rodents. Isoflurane, at anesthetic doses,
increased TrkB phosphorylation and phosphorylation of
CREB within minutes in the adult prefrontal cortex and hip-
pocampus while BDNF levels (mRNA and protein) remained
unchanged (Antila et al. 2017; Theilmann et al. 2019).
Remarkably, a single and brief isoflurane anesthesia produced
antidepressant-like behavioral responses and facilitation of
LTP several hours or a day later after the treatment (Antila
et al. 2017). Antidepressant-like behavioral effects of
isoflurane have been recently reported also by others
(Brown et al. 2018). Similarly with the classical antidepres-
sants, isoflurane regulates TrkB activation also in Bdnf-
deficient mice (Antila et al. 2017) and the effects seem restrict-
ed to adult animals (Rantamäki et al., unpublished).
Halothane, a closely related volatile anesthetic, is reported to
have no antidepressant-like effects (Brown et al. 2018),
although it does regulate TrkB signaling at anesthetic doses
(Antila et al. 2017). It should be noted that of all the tested
pharmacological manipulations so far, deep anesthesia is
clearly one of the most potent and reliable means of inducing
TrkB phosphorylation in the adult rodent brain (Theilmann
et al. 2019). Moreover, we recently showed that
medetomidine, a hypnotic-sedative drug, readily activates
TrkB signaling although it did not bring antidepressant-like
behavioral responses (Kohtala et al. 2018). Notably, as in the
case of monoaminergic antidepressants and lithium, the ef-
fects of isoflurane on TrkB signaling follow closely the phar-
macokinetic profile of the drug (Antila et al. 2017) (Fig. 3).
Rapid-acting antidepressants also act
through TrkB: is the mechanism different
from other antidepressants?
Ketamine is a widely used intravenous analgesic-anesthetic
agent. At low subanesthetic doses (≤ 0.3 mg/kg IV), ketamine
possesses marked analgesic properties with negligible effects
on consciousness and cognition. Ketamine produces dose-
dependent psychotomimetic effects, sedation and ultimately
dissociative anesthesia (≥ 1.0 mg/kg, IV). Importantly, the an-
tidepressant effects of ketamine become evident already at
subanesthetic doses (Berman et al. 2000). A slow IV infusion
of 0.5 mg/kg is routinely delivered in psychiatric practice but
the optimal dose-window for its antidepressant effects remains
to be determined and is likely specific for a given patient (Aan
Het Rot et al. 2012). Anyhow, it is obvious that deep burst-
suppressing EEG (c.f. isoflurane) is not essential for
ketamine’s antidepressant effects.
The molecular mechanisms underlying the antidepressant
effects of ketamine have been extensively studied in animal
models. In most reports, ketamine has been injected intraper-
itoneally at a dose range of 3–10 mg/kg, while few studies
indicate that ketamine might induce antidepressant-like be-
havioral responses also at higher doses and when administered
intravenously (Browne and Lucki 2013). Somewhat similarly
with ECS, subanesthetic treatment of ketamine increases glu-
tamate release and cortical excitability. Here, the inhibition of
NMDA-R and release of the tonic inhibition of GABAergic
interneurons on glutamatergic neurons have been proposed as
one putative mechanism (Duman and Aghajanian 2012).
While also blocking the NMDA-R on glutamatergic neurons,
released glutamate binds and activates preferentially postsyn-
ap t i c AMPA-Rs (amino-3-hydroxy-5-me thy l -4 -
isoxazolepropionic acid receptors). Indeed, AMPA-R block-
ade abolishes antidepressant effects of ketamine in animal
models (Maeng et al. 2008). Ketamine and positive allosteric
modulators of AMPA-Rs upregulate immediate early gene
expression, including the bdnf. Moreover, ketamine has been
shown to increase local translation of BDNF and activation of
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TrkB receptor in the rodent prefrontal cortex and hippocam-
pus (Autry et al. 2011; Monteggia et al. 2013; Yang et al.
2015, 2016; Carreno et al. 2016; Sun et al. 2016; Dong et al.
2017; Ma et al. 2017) (Fig. 1). Ketamine also stimulates
BDNF release in neuronal cultures (Lepack et al. 2016). To
my knowledge however, the ability of ketamine to regulate
TrkB phosphorylation in Bdnf-deficient mice has not been yet
studied. Moreover, the dose-dependent effects of ketamine on
TrkB have not been thoroughly examined in vivo or in vitro.
Among putative intracellular signaling events downstream
of TrkB, activation ofMAPK, activation ofmTor (mammalian
target of rapamycin) (and its target p70S6 kinase) and inhibi-
tion of GSK3β (glycogen synthase 3β) have been intimately
connected with ketamine’s antidepressant effects in animal
models (Li et al. 2010; Beurel et al. 2011). Ketamine regulates
MAPK signaling even in cultured neurons (Lepack et al.
2016). Activation of mTor pathway is thought to underlie
ketamine’s rapid changes on synaptogenesis (Li et al. 2010).
These acute molecular changes are however not specific for
ketamine. For example, isoflurane anesthesia produces very
similar changes on mTor and GSK3β (Kohtala et al. 2016;
Leikas et al. 2017; Antila et al. 2017), without significant
effects on synaptogenesis in adult rodents (De Roo et al.
2009; Antila et al. 2017). Notably, isoflurane, as also several
other general anesthetics (including ketamine), has been
shown to increase synaptogenesis during early postnatal de-
velopment during a time window when BDNF’s ability to
activate TrkB is strongly reduced (De Roo et al. 2009;
Briner et al. 2010, 2011).
Nitrous oxide (N2O), another NMDA-R blocker and a dis-
sociative anesthetic, has been recently shown to produce rapid
antidepressant effects in a subset of patients (Nagele et al.
2015). We revealed that N2O readily regulates Bdnf synthesis
while TrkB signaling remains unchanged during gas adminis-
tration (Kohtala et al. 2018). Importantly, TrkB signaling is set
on only upon gas withdrawal (eliminated within minutes) dur-
ing a brain state dominated by slow EEG oscillations (Kohtala
et al. 2018). Subanesthetic ketamine and flurothyl (a volatile
convulsant analogous to ECT) produce very similar EEG ef-
fects after the acute pharmacological effects on cortical exci-
tation fade (Kohtala et al. 2018). The exact adaptive mecha-
nism that is induced in response to N2O exposure (and other
rapid-acting antidepressants) (Autry et al. 2011; Ly et al.
2018) responsible for the facilitation of TrkB signaling upon
drug withdrawal (Fig. 3) remains under intense study in my
lab.
Conclusions
Essentially, all treatments carrying antidepressant potential have
the ability to rapidly—within an hour—regulate TrkB receptor
signaling and this effect seems to be at the core of the neuro-
trophic and neuroplastic alterations set forth by these treat-
ments. While this effect has not yet unequivocally demonstrat-
ed with ECT (or ECS), our recent study with the volatile con-
vulsant flurothyl supports a notion that convulsive therapies
also facilitate TrkB signaling but only after the epileptiform
activity has dissipated when the brain goes into Ba silent mode,^
a phenomenon thought to predict the efficacy and onset of
action of ECT. TrkB signaling is, however, facilitated also by
a number of agents not carrying antidepressant effects (Autio
et al. 2011; Koskimäki et al. 2014; Antila et al. 2017; Kohtala
et al. 2018) pointing out that TrkB activation per se is not
Fig. 3 Drug-induced TrkB phosphorylation in vivo—under drug
influence or upon drug withdrawal? Monoaminergic antidepressants,
volatile anesthetic and medetomidine rapidly increase TrkB
phosphorylation during the peak of pharmacological effect. Most
clinically effective rapid-acting antidepressants (e.g., subanesthetic
ketamine, nitrous oxide) are thought to regulate TrkB signaling after the
peak of pharmacological effect. p-TrkB, TrkB phosphorylation; TCA,
tricyclic antidepressant; SSRI, serotonin-selective reuptake inhibitor;
ECT, electroconvulsive therapy
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sufficient in antidepressant responses. Future efforts are thus
needed to identify the specific neurobiological basis of how
antidepressants, both conventional and rapid-acting and both
clinically established and putative novel agents effective in an-
imal models, target TrkB signaling (Figs. 1, 2 and 3).
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